iCoat Medical

iCoat Medical is a clinical-stage biotech developing iCM012, a novel therapeutic designed to mitigate ischemia-reperfusion injury during organ transplantation, starting with kidneys. Built on decades of foundational research in thromboinflammation, the company has completed a first-in-human study and is preparing for a Phase IIb trial. With a large, non-cyclical market of over 200,000 annual transplants, iCoat aims to significantly improve graft survival and expand the pool of viable donor organs. The company leverages a deep scientific team with expertise spanning immunology, surgery, and drug development.

Platform based on 25+ years of research into thromboinflammation and the innate immune system, developing therapeutics to coat and protect organs from immune-mediated damage during transplantation.

The field of ischemia-reperfusion injury therapeutics is active but lacks approved, targeted pharmacological agents, representing a white space opportunity. Competition includes other biotechs exploring anti-inflammatory and cytoprotective strategies, as well as improvements in organ preservation solutions. iCoat's specific thromboinflammation-focused approach and direct organ-targeting strategy may provide a differentiated mechanism.